Nerve deafness associated with the use of bortezomib in multiple myeloma:A case report and literature review
Bortezomib is a proteasome inhibitor clinically used to treat multiple myeloma and some lymphomas.Its main adverse reactions include sensory neuropathy,liver function damage,thrombocytopenia,infection,and fatigue.Currently,there are few reports on the impact of bortezomib on the auditory nerve domestically and abroad.A case of multiple myeloma patient who developed peripheral neuropathy,bilateral severe hearing loss,and severe nerve deafness after long-term use of bortezomib is reported.The patient,a 61-year-old male,presented with bone pain for over 2 months and was admitted to Baoding No.1 Hospital for treatment on August 10,2019,where he was diagnosed with multiple myeloma.The patient received standard-dose of VRD(bortezomib,lenalidomide,dexamethasone)regimen chemotherapy,and completed 4 cycles of VRD chemotherapy.Following 4 cycles of VRD chemotherapy,the patient reported a decline in hearing but continued with 9 cycles of chemotherapy.After 5 cycles of maintenance treatment with VD(bortezomib,dexamethasone),a significant progressive decline in hearing occurred,resulting in severe nerve deafness in both ears.Vitamin B1 and mecobalamin were added for treatment for 4 months,and the patient self-reported a significant improvement in hearing compared to before.
万方数据
维普
